8-K: Karyopharm Completes $131M Financing, Restructures Debt

Karyopharm Therapeutics Inc. finalized a $131 million financing and recapitalization, issuing new convertible notes and warrants while restructuring existing debt.

Summary

• Karyopharm Therapeutics Inc. completed a series of financing and recapitalization transactions on October 10, 2025.
• The company borrowed an additional $12.5 million under its amended credit and guaranty agreement.
• It issued $15.0 million in 9.00% Convertible Senior Notes due 2028, maturing October 15, 2028.
• It issued $103.5 million in 9.00% Convertible Senior Notes due 2029, maturing May 13, 2029.
• Existing $100.978 million of 6.00% Convertible Senior Notes due 2029 and associated warrants were exchanged for the new 9.00% Convertible Senior Notes due 2029 and new warrants.
• $15.0 million of existing 6.00% Convertible Senior Notes due 2029 were exchanged for common stock.
• $24.25 million of existing 3.00% Convertible Senior Notes due 2025 were exchanged for common stock and new warrants.
• An additional 1,487,917 shares of Common Stock and warrants to purchase 1,317,771 shares were issued at a combined purchase price of $5.880706 per share and accompanying warrant, with a warrant exercise price of $6.64 per share.
• The new 2028 and 2029 Convertible Notes bear 9.00% interest, with interest for December 31, 2025, and March 31, 2026, paid by capitalizing accrued interest (PIK interest), and thereafter in cash.
• The new notes are secured by a second-priority lien on substantially all assets, junior to the Term Loan and Healthcare Royalty Partners Facility. The 2028 Notes have priority over the 2029 Notes in enforcement proceeds.
• The company's outstanding common stock as of October 14, 2025, is 15,926,939 shares (pre-exercise/conversion of new instruments).
• A consent fee of $1,161,362 was paid in common stock to the Investor Representative for the Healthcare Royalty Partners Facility.

Sentiment

Score: 7

Explanation: The company successfully executed a significant financing and debt restructuring, which provides capital and extends maturities. While it involves new debt and dilution, it addresses immediate financial needs and positions the company for continued operations and product development. The waivers of past defaults and the establishment of clear covenants provide a framework for future financial management.

Positives

• Successfully completed a significant financing and debt restructuring, providing new capital and extending debt maturities.
• The restructuring addresses existing debt, converting some into equity and extending maturities for others, which can improve financial stability.
• Waiver of past defaults under the existing credit and guaranty agreement, clearing previous compliance issues.
• The company maintains a minimum consolidated liquidity covenant of $25,000,000 after the first anniversary of the First Amendment Effective Date, and a dynamic threshold before that, ensuring a cash buffer.
• The company is represented as Solvent upon the consummation of the Recapitalization Transactions.

Negatives

• The issuance of new debt ($118.5 million in convertible notes) increases the company's overall leverage.
• Significant dilution from the issuance of 1,487,917 shares of Common Stock and warrants for 1,317,771 shares, plus shares from debt-to-equity conversions.
• The use of PIK interest for the initial periods of the new convertible notes indicates a desire to conserve cash, potentially reflecting liquidity constraints.
• The new 2029 Convertible Notes are explicitly subordinated to the 2028 Convertible Notes in terms of collateral enforcement proceeds.

Risks

• Failure to maintain minimum consolidated liquidity of $25,000,000 (or the dynamic threshold for the first year post-amendment).
• Defaults on other material indebtedness exceeding $2.5 million individually or $5 million in aggregate.
• Final judgments against the company exceeding $2.5 million individually or $5 million in aggregate.
• ERISA events resulting in liabilities over $25 million.
• Withdrawal of FDA approval for selinexor or adverse modification of its approved indications for use with bortezomib and dexamethasone.
• Breach of covenants in the new debt instruments or other transaction documents.
• Potential for significant liquidated damages if registration statements for resale of securities are not filed or maintained effectively (up to 6.0% of Notional Value).
• The company may possess material non-public information not disclosed to investors, and investors waive claims based on non-disclosure.
• Risks associated with the contingent payment debt instrument tax treatment for the Revenue Interest Financing Agreement.

Future Outlook

The company plans to use commercially reasonable and diligent efforts to secure and maintain Marketing Authorization in the United States for Selinexor and to Commercialize it. It also covenants to file a supplemental New Drug Application (sNDA) for Selinexor in endometrial cancer within nine months of satisfying the Positive SIENDO Study Condition.

Industry Context

The transactions indicate a biotechnology company (Karyopharm Therapeutics) actively managing its debt and equity structure, likely to fund ongoing research, development, and commercialization efforts for its product Selinexor. The focus on oncology indications (multiple myeloma, endometrial cancer, myelofibrosis) for Selinexor places the company in a competitive and capital-intensive segment of the pharmaceutical industry. The debt restructuring and capital raise are common strategies for biotech firms to secure runway for clinical trials and market expansion.

Comparison to Industry Standards

• The 9.00% interest rate on convertible notes is relatively high, reflecting either the company's risk profile or current market conditions for such instruments in the biotech sector.
• The inclusion of PIK interest for initial periods is a common feature in growth-stage company financings to preserve cash.
• The debt-to-equity exchanges and warrant issuances are typical mechanisms for recapitalization and attracting new investment or retaining existing investors.
• The collateral structure (second priority lien, with potential for first priority post-Term Loan) is standard for secured convertible notes, reflecting a balance between investor protection and operational flexibility.
• The minimum liquidity covenant is a common financial safeguard for lenders in the biotech industry, ensuring the company maintains sufficient cash for operations and debt service.

Corporate Governance

Related Party Transactions

• The financing involves several 'Original Holders' (e.g., Highbridge Tactical Credit Institutional Fund, Ltd., Braidwell LP, DavidsonKempner Capital Management LP, Context Capital Management, LLC, HCR Lender) who are also lenders and investors in various capacities, indicating existing relationships.

Stakeholder Impact

• Shareholders: Experience dilution from new stock and warrants, but benefit from improved financial stability and continued operations.
• Noteholders (New): Receive 9.00% interest, collateralized debt, and conversion rights, with some priority over other debt.
• Noteholders (Old): Participate in debt-to-equity or debt-to-new-debt exchanges, potentially altering their risk/reward profile.
• Employees: Benefit from continued company operations and stability.
• Creditors: Existing lenders (Term Loan, Healthcare Royalty Partners Facility) maintain their secured positions, with some debt being restructured.

Next Steps

• File a Registration Statement for resale of Registrable Securities by 45 days after the Closing Date (October 10, 2025).
• Use commercially reasonable efforts to have the Registration Statement declared effective by the SEC by the Effectiveness Deadline (earlier of 90 days after Filing Deadline or 5 Trading Days after Staff notice).
• Use commercially reasonable efforts to secure and maintain Marketing Authorization in the United States for Selinexor.
• File a supplemental New Drug Application (sNDA) with the FDA for Selinexor in endometrial cancer within nine months of satisfying the Positive SIENDO Study Condition.
• Appoint a Board Observer identified by the Requisite Lenders.

Key Dates

Recommendation

The successful completion of a significant financing and debt restructuring is a positive step, addressing immediate liquidity needs and extending debt maturities. However, the high interest rates on new convertible notes, the dilution from new equity and warrants, and the ongoing need for Selinexor's commercialization and further regulatory approvals introduce considerable risk. The company has bought itself time, but the long-term outlook depends heavily on successful product development and market penetration. Investors should hold to monitor the execution of these strategic initiatives and the progress of Selinexor.

Keywords

Karyopharm Therapeutics, Convertible Notes, Debt Restructuring, Equity Financing, SEC Filing, 8-K, Selinexor, Capital Raise, Debt Exchange, NASDAQ, Corporate Finance, Biotechnology